Luspatercept: First Approval.
Markham A.
Drugs. 2020 Jan;80(1):85-90. doi: 10.1007/s40265-019-01251-5.
beta-Thalassaemia.
Thein SL.
Baillieres Clin Haematol. 1993 Mar;6(1):151-75. doi: 10.1016/s0950-3536(05)80069-1.
Beta-thalassaemia.
Thein SL.
Baillieres Clin Haematol. 1998 Mar;11(1):91-126. doi: 10.1016/s0950-3536(98)80071-1.
Hypertriglyceridaemia-thalassaemia syndrome.
Gomber S, Kela K, Abdul Rahiman CL.
Ann Trop Paediatr. 1996 Dec;16(4):359-60. doi: 10.1080/02724936.1996.11747851.
Novel therapies in beta-thalassaemia.
Grech L, Borg K, Borg J.
Br J Clin Pharmacol. 2022 Jun;88(6):2509-2524. doi: 10.1111/bcp.14918. Epub 2021 Jun 4.
The disease burden of beta-thalassaemia revisited.
Soteriades ES, Angastiniotis M, Economidou EC, Farmakis D, Avraam D, Eleftheriou A.
Hematology. 2025 Dec;30(1):2551450. doi: 10.1080/16078454.2025.2551450. Epub 2025 Sep 8.
Thalassaemia in Azerbaijan.
Kuliev AM, Rasulov IM, Dadasheva T, Schwarz EI, Rosatelli C, Saba L, Meloni A, Gemidjioglu E, Petrou M, Modell B.
J Med Genet. 1994 Mar;31(3):209-12. doi: 10.1136/jmg.31.3.209.
Beta-thalassaemia: all roads lead to a cure?
The Lancet Haematology.
Lancet Haematol. 2018 Oct;5(10):e430. doi: 10.1016/S2352-3026(18)30162-5.
Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
Chauhan W, Shoaib S, Fatma R, Zaka-Ur-Rab Z, Afzal M.
Br J Clin Pharmacol. 2022 Aug;88(8):3610-3626. doi: 10.1111/bcp.15343. Epub 2022 Apr 18.
Molecular therapies in beta-thalassaemia.
Quek L, Thein SL.
Br J Haematol. 2007 Feb;136(3):353-65. doi: 10.1111/j.1365-2141.2006.06408.x. Epub 2006 Nov 27.
